Dialysate Cancer Antigen 125 Concentration as Marker of Peritoneal Membrane Status in Patients Treated with Chronic Peritoneal Dialysis

Bast R.C. Jr. , Feeney M. , Lazarus H. , Nadler L.M. , Colvin R.B. , Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–7.

Kabawat S.E. , Bast R.C. Jr. , Bhan A.K. , Welch W.R. , Knapp R.C. , Colvin R.B. Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 1983; 2: 275–85.

Bast R.C. Jr. , Klug T.L. , St John E. , Jenison E. , Niloff J.M. , Lazarus H. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–7.

Jacobs L. , Stabile I. , Bridges J. , Kemsley P. , Reynolds C. , Grudzinskas J. Multimodal approach to screening for ovarian cancer. Lancet 1988; 1: 268–71.

Malkasian G.D. , Knapp R.C. , Lavin P.T. , Zurawski V.R. , Podrate K.C. , Stanhope R. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341–6.

Patsner B. , Mann W.J. The value of preoperative serum CA125 levels in patients with a pelvic mass. Am J Obstet Gynecol 1988; 159: 873–6.

Zurawski V.R. , Orjaseter H. , Anderson A. , Jellum E. Elevated serum CA125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer. Int J Cancer 1988; 42: 677–80.

Bon G.J. , Kenemans P. , Verstraeten R. , Van Kamp G.J. , Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values. Am J Obstet Gynecol 1996; 174: 107–14.

Buller R.E. , Vasilev S. , DiSaia P.J. CA 125 kinetics: A cost-effective clinical tool to evaluate trial outcomes in the 1990s. Am J Obstet Gynecol 1996; 174: 1241–54.

Jacobs I. , Bast R.C. Jr. The CA125 tumor-associated antigen: A review of the literature. Hum Reprod 1989; 4: 1–12.

Van der Burg M.E.L. , Lammes F.B. , Verweij J. CA125 in ovarian cancer. Neth J Med 1992; 40: 36–51.

Macdonald F. , Downing R. , Allum W.H. Expression of CA125 in pancreatic carcinoma and chronic pancreatitis. Br J Cancer 1998; 58: 505–6.

O'Brien T.J. , Hardin J.W. , Bannon G.A. , Norvis J.S. , Quirk G. Jr. CA 125 antigen in human amniotic fluid and fetal membranes. Am J Obstet Gynecol 1986; 155: 50–5.

O'Brien T.J. , Raymond L.M. , Bannon G.A. , Ford H.D. , Hardartottir H. , Miller F.C. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 1991; 165: 1857–64.

Davis H.M. , Zurawski V.R. , Bast R.C. Jr. , Klug T.L. Characterization of the CA125 antigen associated with human epithelial ovarian carcinomas. Cancer Res 1986; 46: 6143–8.

Barbieri R.L. , Niloff J.M. , Bast R.C. Jr. , Schnaetze E. , Kistner R.W. , Knapp R.C. Elevated serum concentrations of CA125 in patients with advanced endometriosis. Fertil Steril 1986; 45: 630–4.

Halila H. , Steuman U.H. , Seppula M. Ovarian cancer antigen CA125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327–9.

Simseh H. , Kadayifci A. , Okan E. High serum level of CA125 in malignant peritoneal mesothelioma. Eur J Cancer 1995; 31: 129.

Molina R. , Filella X. , Bruix J. , Mengual P. , Bosch J. , Colvet X. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 1991; 37: 1379–83.

Ismail M. , Rotmensch J. , Mercer L.J. , Block B.S. , Salti G.I. , Holt J.A. CA125 in peritoneal fluid from patients with nonmalignant gynecologic disorders. J Reprod Med 1994; 39: 510–12.

Onsrud M. , Shabana A. , Austgullen R. , Nustad K. Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer. Gynecol Oncol 1995; 57: 183–7.

Redman C.W.E. , Jones S.R. , Luesley D.M. , Nicholl S.E. , Kelly K. , Buxton E.J. Peritoneal trauma releases CA125? Br J Cancer 1988; 58: 502–4.

Stylianou E. , Jenner L.A. , Davies M. , Coles G.A. , Williams J.D. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990; 37: 1563–70.

Betjes M.G.H. , Tak C.W. , Struijk D.G. , Krediet R.T. , Arisz L. , Beelen R.H.J. Adherence of staphylococci to plastic, mesothelial cells and mesothelial extracellular matrix. Adv Perit Dial 1992; 8: 215–18.

Koomen G.C.M. , Betjes M.G.H. , Zemel D. , Krediet R.T. , Hoek F.J. Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14: 132–6.

Visser C.E. , Brouwer–Steenbergen J.J.E. , Betjes M.G.H. , Koomen G.C.M. , Beelen R.H.J. , Krediet R.T. Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10: 64–9.

Zeillemaker A.M. , Verbrugh H.A. , Hoynck van Papendrecht AAGM , Leguit P. CA125 secretion by peritoneal mesothelial cells. J Clin Pathol 1994; 47: 263–5.

Cases A. , Filella X. , Molina R. , Ballesta A.M. , Lopez–Pedret J. , Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57: 183–6.

Zeferos N. , Digenis G.E. , Christophoraki M. , Alexopoulos I. , Kostakis A. , Gyftahi H. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron 1991; 59: 618–20.

Menzin A.W. , Kobrin S. , Pollak E. , Goodman D.B.P. , Rubin S.C. The effect of renal function on serum levels of CA125. Gynecol Oncol 1995; 58: 375–7.

Passadakis P. , Panagoutsos S. , Thodis E. , Tsivara I. , Sopassi F. , Kartali S. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 1999; 15: 40–4.

Lye W.C. , Tambyah P. , Leong S.O. , Lee E.J.C. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial 1994; 10: 109–11.

Kawabe T. , Ishii M. , Sugimoto T. , Tagawa H. Low serum CA125 concentration in chronic renal failure treated with continuous ambulatory peritoneal dialysis. Clin Chim Acta 1987; 168: 113–14.

Bastiani B. , Chu H. Serum CA125 in chronic peritoneal dialysis (PD) patients: The effect of PD catheter implantation and peritonitis. J Am Soc Nephrol 1993; 4(Suppl 2): 397.

Pannekeet M.M. , Zemel D. , Koomen G.C.M. , Struijk D.G. , Krediet R.T. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 1995; 15: 217–25.

Topley N. The host's initial response to peritoneal infection: The pivotal role of the mesothelial cell. Perit Dial Int 1995; 15: 116–17.

Topley N. , Coles G.A. , Williams J.D. Biocompatibility studies on peritoneal cells. Perit Dial Int 1994; 14(Suppl 3): S21–8.

Breborowicz A. , Rodela H. , Oreopoulos D.G. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992; 41: 1280–5.

Witowski J. , Topley N. , Jörres A. , Liberek T. , Coles G.A. , Williams J.D. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1994; 46: 282–93.

Yang A.H. , Chen J.Y. , Lin Y.P. , Huang T.P. , Wu C.W. Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 1997; 51: 1280–8.

Witowski J. , Jörres A. Glucose degradation products: Relationship with cell damage. Perit Dial Int 2000; 20(Suppl 2): S31–6.

Pederson F.B. , Ryttov N. , Deluran P. , Drugsholt C. , Kildeberg P. Acetate versus lactate in peritoneal dialysis solutions. Nephron 1985; 39: 55–8.

Gotloib L. , Shostak A. , Wajsbrot V. , Kuschnier R. The cytochemical profile of visceral mesothelium under the influence of lactated-hyper osmolar peritoneal dialysis solutions. Nephron 1995; 69: 466–71.

Gotloib L. , Wajsbrot V. , Shostak A. , Kuschnier R. Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, lactated, buffered dialysis solutions. Nephron 1995; 70: 466–77.

Wajsbrot V. , Shostak A. , Gotloib L. , Kushnier R. Biocompatibility of a glucose-free acidic lactated solution for peritoneal dialysis evaluated by population analysis of mesothelium. Nephron 1998; 79: 322–32.

Gotloib L. , Wajsbrot V. , Shostak A. , Kushnier R. Effect of hyperosmolality upon the mesothelial monolayer exposed in vivo and in situ to a mannitol-enriched dialysis solution. Nephron 1999; 81: 301–9.

Dobbie J.W. , Zaki M. , Wilson L. Ultrastructural studies on the peritoneum with special reference to chronic ambulatory peritoneal dialysis. Scott Med J 1981; 26: 213–23.

Di Paolo N. , Sacchi G. , De Mia M. , Gaggiotti E. , Capotondo L. , Rossi R. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis. Nephron 1986; 44: 204–11.

Gotloib L. , Shostak A. , Bar-Sella P. , Cohen R. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Bull 1987; 7: 148–55.

Dobbie J.W. Morphology of the peritoneum in CAPD. Blood Purif 1989; 7: 74–85.

Pollock C.A. , Ibels L.S. , Eckstein R.P. , Graham J.C. , Caterson R.J. , Mahony J.F. Peritoneal morphology on maintenance dialysis. Am J Nephrol 1989; 9: 198–204.

Dobbie J.W. , Lloyd J.K. , Gall C.A. Categorization of ultra-structural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990; 6: 3–12.

Di Paolo N. , Sacchi G. The peritoneum during peritoneal dialysis. In: Di Paolo N. , Sacchi G. , eds. Atlas of peritoneal histology. Perit Dial Int 2000; 20(Suppl 3): S37–63.

Dobbie J.W. , Anderson J.D. , Hind C. Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 1994; 14(Suppl 3): S16–20.

Dobbie J.W. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14–27.

Suassuna J.H.R. , Das Neves F.C. , Hartley B. , Ogg C.S. , Cameron J.S. Immunohistochemical studies of the peritoneal membrane and infiltrating cells in normal subjects and patients on CAPD. Kidney Int 1994; 46: 443–54.

Dobbie J.W. New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis. Am J Kidney Dis 1990; 15: 97–109.

Ho-dac-Pannekeet M.M. , Hiralall J.K. , Struijk D.G. , Krediet R.T. Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51: 888–93.

Pannekeet M.M. , Koomen G.C.M. , Struijk D.G. , Krediet R.T. Dialysate CA125 in stable CAPD patients: No relation with transport parameters. Clin Nephrol 1995; 44: 248–54.

Wong E.C.C. Difficulties in analysis of CA125 in diluted samples. Clin Chem 1995; 41: 1543–4.

Sanusi A.A. , Zweers M.M. , Weening J.J. , de Waart D.R. , Struijk D.G. , Krediet R.T. Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis. Perit Dial Int 2001; 21: 495–500.

Lai K.N. , Lai K.B. , Szeto C.C. , Ho K.K.L. , Poon P. , Lam C.W.K. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: Their relationship with transport parameters. Am J Kidney Dis 1997; 29: 699–705.

Jimenez C. , Diaz C. , Selgas R. , Bajo M.A. , Del Peso G. , Sánchez–Tomero J.A. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: The relationship with peritoneal outcome. Adv Perit Dial 1999; 15: 36–9.

Kawanishi H. , Moriishi M. , Harada Y. , Sakikubo E. , Nagai T. , Tsuchiya S. Necessity of correcting cancer antigen 125 appearance rates by body surface area. Adv Perit Dial 2000; 16: 22–5.

Ozener I.C. , Sirikci O. , Koc M. Dialysate CA125 concentrations in continuous peritoneal dialysis (CAPD) patients (Abstract). Nephrol Dial Transplant 2000; 15: A229.

Bouts A.H.M. , Groothoff J.W. , Ploos van Amstel S. , Zweers M.M. , Davin J-C , Krediet R.T. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis. Adv Perit Dial 2000; 16: 328–31.

Flessner M. Osmotic barrier of the parietal peritoneum. Am J Physiol 1994; 267: F861–70.

Pietrzak I. , Hirszel P. , Shostak A. , Welch P.G. , Lee R.E. , Maher J.F. Splanchnic volume, not flow rate, determines peritoneal permeability. ASAIO Trans 1989; 35: 583–7.

Douma C.E. , De Waart D.R. , Struijk D.G. , Krediet R.T. The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD. Kidney Int 1997; 51: 1885–92.

Ho-dac-Pannekeet M.M. , Krediet R.T. Inflammatory changes in vivo during CAPD: what can the effluent tell us? Kidney Int 1966; 50(Suppl 56): S12–16.

Zemel D. , Koomen G.C.M. , Hart A.A.M. , Ten Berge R.J.M. , Struijk D.G. , Krediet R.T. Relationship of TNF-a, interleukin-6 and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1993; 122: 686–96.

Zemel D. , Struijk D.G. , Dinkla C. , Stolk L.M. , Ten Berge R.J.M. , Krediet R.T. Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis. J Lab Clin Med 1995; 126: 204–15.

Zemel D. , Krediet R.T. Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: Relationship to peritoneal permeability. Blood Purif 1996; 14: 198–216.

Fusshöller A. , Grabensee B. , Plum J. CA125 in the effluent of chronic peritoneal dialysis (PD) patients: Relation to transport parameters, peritonitis, PD duration, and regime (Abstract). Perit Dial Int 2000; 20(Suppl 1): S7.

Hagmolen of ten Have W, Ho-dac-Pannekeet M.M. , Struijk D.G. , Krediet R.T. Mesothelial regeneration after peritonitis in dialysis patients (Abstract). J Am Soc Nephrol 1997; 8: 180A.

Ho-dac-Pannekeet M.M. , Hiralall J.K. , Struijk D.G. , Krediet R.T. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 1997; 13: 72–6.

Ileri T. , Söylemezoglu O. , Sindel S. , Özkaya O. , Derici Ü , Arinsoy T. The predictive value of cancer antigen 125 (CA125), collagen III, plasminogen activator inhibitor type-1 (PAI-1), basic fibroblast growth factor (bFGF) on peritoneal fibrosis in chronic peritoneal dialysis (Abstract). Nephrol Dial Transplant 2000; 15: A234.

Ho-dac-Pannekeet M.M. Assessment of peritoneal permeability and mesothelial cell mass in peritoneal dialysis patients (Thesis). Amsterdam: University of Amsterdam, 1997.

Burkart J. , Stallard R. Result of peritoneal membrane (PM) resting (R) on dialysate (d) CA125 levels and PET results (Abstract). Perit Dial Int 1997; 17(Suppl 1): S5.

Moriishi M. , Sakikubo E. , Asakimori Y. , Kumagai J. , Skintaku S. , Tsuchiya S. CA125 appearance rate is useful marker for peritoneal sclerosis in long-term CAPD patients (Abstract). Perit Dial Int 1998; 18(Suppl 2): S90.

Miranda B. , Selgas R. , Celadilla O. , Muñoz J. , Sánchez–Sicilia L. Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD. Contrib Nephrol 1991; 89: 199–204.

Da Alvaro F. , Castro M.J. , Dapena F. , Bajo M.A. , Fernandez–Reyes M.J. , Romero J.R. Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure. Adv Perit Dial 1993; 9: 56–61.

Moriishi M. , Kawanishi H. , Katsutani M. , Harada Y. , Sakikubo E. , Matsumoto T. Peritoneal resting in long-term peritoneal dialysis patients (Abstract). Perit Dial Int 2000; 20(Suppl 1): S11.

Hebah N. Ultrafiltration failure (UFF) in long-term peritoneal dialysis (PD): A case report (Abstract). Perit Dial Int 2000; 20: 127.

Krediet R.T. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999; 55: 341–56.

Ho-dac-Pannekeet M.M. Peritoneal fluid markers of mesothelial cells and function. Adv Ren Replace Ther 1998; 5: 205–11.

Simonsen O. , Wieslander A. , Landgren C. , Rippe B. Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid. Adv Perit Dial 1996; 12: 156–60.

Cappelli G. , Bandiani G. , Cancarini G.C. , Feriani M. , Dell'Aquila R. , Saffioti S. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag. Adv Perit Dial 1999; 15: 238–42.

Rippe B. , Simonsen O. , Heimbürger O. , Christensson A. , Haraldsson B. , Stelin G. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348–57.

Jones S. , Holmes C.J. , Krediet R.T. , Mackenzie R. , Faict D. , Tranæus A. Continuous dialysis with bicarbonate/lactate based peritoneal dialysis solution is associated with an increase in dialysate CA125 and a decrease in hyaluronic acid (HA) levels. Kidney Int 2001; 59: 1529–38.